{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:06:20Z","timestamp":1765728380797,"version":"3.37.3"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s00508-010-1313-5","type":"journal-article","created":{"date-parts":[[2010,3,6]],"date-time":"2010-03-06T05:59:26Z","timestamp":1267855166000},"page":"65-74","source":"Crossref","is-referenced-by-count":7,"title":["Aldosteron und Hypertonie","The role of aldosterone in hypertension"],"prefix":"10.1007","volume":"122","author":[{"given":"Oliver","family":"Vonend","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Quack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Christian","family":"Rump","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,1]]},"reference":[{"issue":"4","key":"1313_CR1","first-page":"661","volume":"45","author":"JW Conn","year":"1955","unstructured":"Conn JW (1955) Primary aldosteronism. J Lab Clin Med 45 (4): 661\u2013664","journal-title":"J Lab Clin Med"},{"issue":"1","key":"1313_CR2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan RS, et al (2004) Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351 (1): 33\u201341","journal-title":"N Engl J Med"},{"issue":"1","key":"1313_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00004872-200201000-00017","volume":"20","author":"MP Schlaich","year":"2002","unstructured":"Schlaich MP, et al (2002) Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension. J Hypertens 20 (1): 117\u2013124","journal-title":"J Hypertens"},{"issue":"4","key":"1313_CR4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","volume":"19","author":"M Sartori","year":"2006","unstructured":"Sartori M, et al (2006) Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 19 (4): 373\u2013379 (discussion 380)","journal-title":"Am J Hypertens"},{"issue":"2","key":"1313_CR5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, et al (2002) Efficacy of eplerenone added to reninangiotensin blockade in hypertensive patients. Hypertension 40 (2): 117\u2013123","journal-title":"Hypertension"},{"issue":"4","key":"1313_CR6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, et al (2007) Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 (4): 839\u2013845","journal-title":"Hypertension"},{"issue":"4","key":"1313_CR7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","volume":"25","author":"DA Lane","year":"2007","unstructured":"Lane DA, Shah S, Beevers DG (2007) Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 25 (4): 891\u2013894","journal-title":"J Hypertens"},{"issue":"3","key":"1313_CR8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","volume":"46","author":"C Saha","year":"2005","unstructured":"Saha C, et al (2005) Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46 (3): 481\u2013487","journal-title":"Hypertension"},{"issue":"7","key":"1313_CR9","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.amjhyper.2005.11.016","volume":"19","author":"Y Sharabi","year":"2006","unstructured":"Sharabi Y, et al (2006) Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 19 (7): 750\u2013755","journal-title":"Am J Hypertens"},{"issue":"11","key":"1313_CR10","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"KJ Schjoedt","year":"2004","unstructured":"Schjoedt KJ, et al (2004) Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47 (11): 1936\u20131939","journal-title":"Diabetologia"},{"issue":"9","key":"1313_CR11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3 (9): 486\u2013492","journal-title":"Nat Clin Pract Nephrol"},{"issue":"1","key":"1313_CR12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ndt\/gfl549","volume":"22","author":"LC Rump","year":"2007","unstructured":"Rump LC (2007) Secondary rise of albuminuria under AT1-receptor blockade \u2013 what is the potential role of aldosterone escape? Nephrol Dial Transplant 22 (1): 5\u20138","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"1313_CR13","first-page":"2519","volume":"85","author":"KM Kayes-Wandover","year":"2000","unstructured":"Kayes-Wandover KM, White PC (2000) Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 85 (7): 2519\u20132525","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1313_CR14","first-page":"2797","volume":"81","author":"Y Takeda","year":"1996","unstructured":"Takeda Y, et al (1996) Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 81 (8): 2797\u20132800","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1313_CR15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (10): 709\u2013717","journal-title":"N Engl J Med"},{"issue":"14","key":"1313_CR16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (14): 1309\u20131321","journal-title":"N Engl J Med"},{"issue":"1","key":"1313_CR17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00424-009-0656-0","volume":"458","author":"J Loffing","year":"2009","unstructured":"Loffing J, Korbmacher C (2009) Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC). Pflugers Arch 458 (1): 111\u2013135","journal-title":"Pflugers Arch"},{"issue":"6","key":"1313_CR18","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1210\/jc.2003-030373","volume":"88","author":"PC White","year":"2003","unstructured":"White PC (2003) Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab 88 (6): 2376\u20132383","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1313_CR19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MNH.0b013e3282f56854","volume":"17","author":"MJ Young","year":"2008","unstructured":"Young MJ (2008) Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens 17 (2): 174\u2013180","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"15","key":"1313_CR20","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, et al (2003) Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 (15): 1831\u20131838","journal-title":"Circulation"},{"issue":"13","key":"1313_CR21","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1161\/01.CIR.0000142858.44680.27","volume":"110","author":"A Garnier","year":"2004","unstructured":"Garnier A, et al (2004) Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110 (13): 1819\u20131825","journal-title":"Circulation"},{"issue":"2","key":"1313_CR22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0735-1097(01)01729-6","volume":"39","author":"J Bauersachs","year":"2002","unstructured":"Bauersachs J, et al (2002) Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39 (2): 351\u2013358","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1313_CR23","doi-asserted-by":"crossref","first-page":"H423","DOI":"10.1152\/ajpheart.00685.2001","volume":"283","author":"ZH Zhang","year":"2002","unstructured":"Zhang ZH, et al (2002) The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol 283 (1): H423\u2013433","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"1313_CR24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/jc.2008-2116","volume":"94","author":"E Born-Frontsberg","year":"2009","unstructured":"Born-Frontsberg E, et al (2009) Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 94 (4): 1125\u20131130","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1313_CR25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00059-006-2821-y","volume":"31","author":"N Buchner","year":"2006","unstructured":"Buchner N, Vonend O, Rump LC (2006) Pathophysiology of hypertension: what's new? Herz 31 (4): 294\u2013302","journal-title":"Herz"},{"issue":"8","key":"1313_CR26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.ki.5002006","volume":"71","author":"JR Sowers","year":"2007","unstructured":"Sowers JR (2007) Metabolic risk factors and renal disease. Kidney Int 71 (8): 719\u2013720","journal-title":"Kidney Int"},{"issue":"11","key":"1313_CR27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","volume":"150","author":"JR Sowers","year":"2009","unstructured":"Sowers JR, Whaley-Connell A, Epstein M (2009) Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 150 (11): 776\u2013783","journal-title":"Ann Intern Med"},{"issue":"10","key":"1313_CR28","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1161\/01.CIR.0000140677.20606.0E","volume":"110","author":"S Malik","year":"2004","unstructured":"Malik S, et al (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (10): 1245\u20131250","journal-title":"Circulation"},{"issue":"3","key":"1313_CR29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/01.HYP.37.3.845","volume":"37","author":"AH El-Gharbawy","year":"2001","unstructured":"El-Gharbawy AH, et al (2001) Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 37 (3): 845\u2013850","journal-title":"Hypertension"},{"issue":"3\u20134","key":"1313_CR30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/07435809809032689","volume":"24","author":"TL Goodfriend","year":"1998","unstructured":"Goodfriend TL, Egan BM, Kelley DE (1998) Aldosterone in obesity. Endocr Res 24 (3\u20134): 789\u2013796","journal-title":"Endocr Res"},{"issue":"4","key":"1313_CR31","doi-asserted-by":"crossref","first-page":"H2009","DOI":"10.1152\/ajpheart.00522.2007","volume":"293","author":"SA Cooper","year":"2007","unstructured":"Cooper SA, et al (2007) Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293 (4): H2009\u20132023","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"11","key":"1313_CR32","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","volume":"119","author":"M Epstein","year":"2006","unstructured":"Epstein M (2006) Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 119 (11): 912\u2013919","journal-title":"Am J Med"},{"issue":"9","key":"1313_CR33","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1097\/00004872-200209000-00023","volume":"20","author":"P Russo","year":"2002","unstructured":"Russo P, et al (2002) Interaction between the C (\u2013344)T polymorphism of CYP11B2 and age in the regulation of blood pressure and plasma aldosterone levels: cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study. J Hypertens 20 (9): 1785\u20131792","journal-title":"J Hypertens"},{"issue":"1","key":"1313_CR34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s001090000144","volume":"79","author":"S Engeli","year":"2001","unstructured":"Engeli S, Sharma AM (2001) The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 79 (1): 21\u201329","journal-title":"J Mol Med"},{"issue":"24","key":"1313_CR35","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.2336140100","volume":"100","author":"M Ehrhart-Bornstein","year":"2003","unstructured":"Ehrhart-Bornstein M, et al (2003) Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 100 (24): 14211\u201314216","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1313_CR36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ncpcardio0319","volume":"2","author":"G Iacobellis","year":"2005","unstructured":"Iacobellis G, Corradi D, Sharma AM (2005) Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2 (10): 536\u2013543","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"1313_CR37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jama.1965.03090030022005","volume":"193","author":"JW Conn","year":"1965","unstructured":"Conn JW, et al (1965) Normokalemic primary aldosteronism. A detectable cause of curable \"Essential\" hypertension. JAMA 193: 200\u2013206","journal-title":"JAMA"},{"issue":"5","key":"1313_CR38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1590\/S0004-27302004000500012","volume":"48","author":"RD Gordon","year":"2004","unstructured":"Gordon RD (2004) Primary aldosteronism \u2013 actual epidemics or false alarm? Arq Bras Endocrinol Metabol 48 (5): 666\u2013673","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"5","key":"1313_CR39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/sj.jhh.1001013","volume":"14","author":"PO Lim","year":"2000","unstructured":"Lim PO, et al (2000) High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14 (5): 311\u2013315","journal-title":"J Hum Hypertens"},{"issue":"11","key":"1313_CR40","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, et al (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48 (11): 2293\u20132300","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1313_CR41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1373\/clinchem.2004.041780","volume":"51","author":"GL Schwartz","year":"2005","unstructured":"Schwartz GL, Turner ST (2005) Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51 (2): 386\u2013394","journal-title":"Clin Chem"},{"issue":"9628","key":"1313_CR42","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","volume":"371","author":"S Douma","year":"2008","unstructured":"Douma S, et al (2008) Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371 (9628): 1921\u20131926","journal-title":"Lancet"},{"issue":"2","key":"1313_CR43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","volume":"42","author":"L Mosso","year":"2003","unstructured":"Mosso L, et al (2003) Primary aldosteronism and hypertensive disease. Hypertension 42 (2): 161\u20135","journal-title":"Hypertension"},{"issue":"6","key":"1313_CR44","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1210\/en.2003-0279","volume":"144","author":"WF Young Jr","year":"2003","unstructured":"Young WF Jr (2003) Minireview: primary aldosteronism \u2013 changing concepts in diagnosis and treatment. Endocrinology 144 (6): 2208\u20132213","journal-title":"Endocrinology"},{"issue":"22","key":"1313_CR45","first-page":"1109","volume":"95","author":"DJ Sutherland","year":"1966","unstructured":"Sutherland DJ, Ruse JL, Laidlaw JC (1966) Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 95 (22): 1109\u20131119","journal-title":"Can Med Assoc J"},{"issue":"3","key":"1313_CR46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1161\/HYPERTENSIONAHA.107.101915","volume":"51","author":"I Quack","year":"2008","unstructured":"Quack I, et al (2008) A tale of two patients with Mendelian hypertension. Hypertension 51 (3): 609\u2013614","journal-title":"Hypertension"},{"issue":"4","key":"1313_CR47","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/ndt\/gfl706","volume":"22","author":"O Vonend","year":"2007","unstructured":"Vonend O, et al (2007) A German family with glucocorticoid-remediable aldosteronism. Nephrol Dial Transplant 22 (4): 1123\u20131130","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1313_CR48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1440-1681.1992.tb00462.x","volume":"19","author":"M Stowasser","year":"1992","unstructured":"Stowasser M, et al (1992) Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 19 (5): 319\u2013322","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"11","key":"1313_CR49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/jmg.37.11.831","volume":"37","author":"AR Lafferty","year":"2000","unstructured":"Lafferty AR, et al (2000) A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 37 (11): 831\u2013815","journal-title":"J Med Genet"},{"issue":"8","key":"1313_CR50","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.hjh.0000174299.66369.26","volume":"23","author":"A So","year":"2005","unstructured":"So A, et al (2005) Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 23 (8): 1477\u20131484","journal-title":"J Hypertens"},{"issue":"4","key":"1313_CR51","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","volume":"49","author":"C Newton-Cheh","year":"2007","unstructured":"Newton-Cheh C, et al (2007) Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 49 (4): 846\u2013856","journal-title":"Hypertension"},{"issue":"8","key":"1313_CR52","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1210\/jc.2008-0594","volume":"93","author":"DS Geller","year":"2008","unstructured":"Geller DS, et al (2008) A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 93 (8): 3117\u20133123","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1313_CR53","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","volume":"93","author":"JW Funder","year":"2008","unstructured":"Funder JW, et al (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93 (9): 3266\u20133281","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"1313_CR54","first-page":"305","volume":"106","author":"C Schirpenbach","year":"2009","unstructured":"Schirpenbach C, et al (2009) The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Dtsch Arztebl Int 106 (18): 305\u2013311","journal-title":"Dtsch Arztebl Int"},{"key":"1313_CR55","first-page":"A181","volume":"100","author":"M Reincke","year":"2003","unstructured":"Reincke M, Seiler L, Rump LC (2003) Normokali\u00e4mischer prim\u00e4rer Hyperaldosteronismus. Dtsch Arztebl 100: A181\u2013190","journal-title":"Dtsch Arztebl"},{"issue":"1","key":"1313_CR56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2362.2008.02060.x","volume":"39","author":"HS Willenberg","year":"2009","unstructured":"Willenberg HS, et al (2009) The serum sodium to urinary sodium to (serum potassium)2 to urinary potassium (SUSPPUP) ratio in patients with primary aldosteronism. Eur J Clin Invest 39 (1): 43\u201350","journal-title":"Eur J Clin Invest"},{"issue":"12","key":"1313_CR57","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.amjhyper.2007.08.009","volume":"20","author":"F Pizzolo","year":"2007","unstructured":"Pizzolo F, et al (2007) Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy. Am J Hypertens 20 (12): 1334\u2013137","journal-title":"Am J Hypertens"},{"issue":"10","key":"1313_CR58","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1210\/jc.2009-1399","volume":"94","author":"M Stowasser","year":"2009","unstructured":"Stowasser M (2009) Update in primary aldosteronism. J Clin Endocrinol Metab 94 (10): 3623\u20133630","journal-title":"J Clin Endocrinol Metab"},{"issue":"46","key":"1313_CR59","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1055\/s-2007-991669","volume":"132","author":"O Vonend","year":"2007","unstructured":"Vonend O, et al (2007) Comparison of adrenal imaging and selective adrenal vein sampling in primary hyperaldosteronism. Dtsch Med Wochenschr 132 (46): 2436\u20132441","journal-title":"Dtsch Med Wochenschr"},{"issue":"Suppl 1","key":"1313_CR60","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1148\/rg.25si055514","volume":"25","author":"N Daunt","year":"2005","unstructured":"Daunt N (2005) Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 25 [Suppl 1]: S143\u2013158","journal-title":"Radiographics"},{"issue":"8","key":"1313_CR61","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1210\/jc.2002-022051","volume":"88","author":"EA Espiner","year":"2003","unstructured":"Espiner EA, et al (2003) Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. J Clin Endocrinol Metab 88 (8): 3637\u20133644","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1313_CR62","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/HJH.0b013e3282f9e66a","volume":"26","author":"GP Rossi","year":"2008","unstructured":"Rossi GP, et al (2008) Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens 26 (5): 989\u2013997","journal-title":"J Hypertens"},{"issue":"5","key":"1313_CR63","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1161\/HYPERTENSIONAHA.108.128553","volume":"53","author":"TM Seccia","year":"2009","unstructured":"Seccia TM, et al (2009) Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension 53 (5): 761\u2013766","journal-title":"Hypertension"},{"issue":"10","key":"1313_CR64","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"X Jeunemaitre","year":"1987","unstructured":"Jeunemaitre X, et al (1987) Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 60 (10): 820\u2013825","journal-title":"Am J Cardiol"},{"issue":"5","key":"1313_CR65","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-60-5-896","volume":"60","author":"JL Nadler","year":"1985","unstructured":"Nadler JL, Hsueh W, Horton R (1985) Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab 60 (5): 896\u2013899","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1313_CR66","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","volume":"55","author":"F de Souza","year":"2010","unstructured":"de Souza F, et al (2010) Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 55 (1): 147\u2013152","journal-title":"Hypertension"},{"issue":"2","key":"1313_CR67","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","volume":"240","author":"M de Gasparo","year":"1987","unstructured":"de Gasparo M, et al (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240 (2): 650\u2013656","journal-title":"J Pharmacol Exp Ther"},{"issue":"17","key":"1313_CR68","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","volume":"29","author":"P Mulder","year":"2008","unstructured":"Mulder P, et al (2008) Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 29 (17): 2171\u20132179","journal-title":"Eur Heart J"},{"issue":"4","key":"1313_CR69","first-page":"319","volume":"10","author":"PM Jansen","year":"2009","unstructured":"Jansen PM, van den Meiracker AH, Jan Danser AH (2009) Aldosterone synthase inhibitors: pharmacological and clinical aspects. Curr Opin Investig Drugs 10 (4): 319\u2013326","journal-title":"Curr Opin Investig Drugs"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-010-1313-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-010-1313-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-010-1313-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T01:26:20Z","timestamp":1739928380000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-010-1313-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":69,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1007\/s00508-010-1313-5","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}